Search This Blog

Biopharma Over Coffee

Updates on recent goings on in the pharma, biotech and healthcare sectors.

Posts

Showing posts with the label HEOR

Show all

February 06, 2025

Disrupting HTA and HEOR: the role of AI

Get link
Facebook
X
Pinterest
Email
Other Apps

Older Posts Home

Powered by Blogger

Doug Niven: Each week, an article will cover something that you may have missed in the pharma, biotech or healthcare news, and perfect to read over a cup of coffee.

Visit profile

Followers

Labels

3D Printing1
Acumen2
adagrasib2
Adaptimmune1
alpha synuclein2
ALS2
Alzheimer's Disease3
Amlyx1
AMX00351
amyloid beta2

antimicrobials1
Artificial Intelligence1
AskBio2
ATMP3
Bayer2
Bial2
Biogen1
biomarkers2
biotech1
Cell and Gene Therapy2
clinical development3
clinical effectiveness1
clinical studies6
CMS1
colorectal cancer2
commercialisation1
commercialization3
decentralized manufacturing1
Disease Modifying Therapies2
Distal Genes2
Donald Trump2
donanemab3
drug approval2
drug development7
Drug Discovery1
drug pricing6
Drug Repurposing2
Drug Supply1
EFPIA1
Eisai1
Eli Lilly2
EMA5
EPF1
EU1
European Commission1
European Parliament1
European Union2
Executive Order1
Fabhalta2
FDA9
G-BA1
GBA2
genetic medicine1
Genome1
GLP-1R2
HAS1
health economics2
Health Technology Assessment2
HEOR1
HTA4
IBD1
Ibudilast1
ICER3
Immuno-oncology1
Inflammation2
Inflammatory Bowel Disease2
international reference pricing1
ION3631
JCA2
Joint Clinical Assessment2
Kinase Inhibitors2
KISUNLA1
KISUNLI2
KRAS mutations2
KRAZATI2
lecanemab3
LEQEMBI3
loss of exclusivity1
LUMAKRAS2
Machine Learning1
macitinib1
Macrophages1
manufacturing1
market access6
Market Exclusivity1
medicaid1
medicare1
mild cognitive impairment1
most favored nation1
neuroprotection2
NICE1
Novartis3
NSCLC2
oncology3
Orphan Drugs4
pancreatic cancer2
Parkinson's Disease2
Personalised therapy1
personalization1
pharma1
pharmaceuticals1
Pharmaceuticals Legislation1
Pharmacy1
PICO1
pipeline1
PNH2
price negotiations1
pricing2
Prime C1
rare diseases6
real world evidence1
Regulation1
regulatory3
regulatory affairs1
regulatory pathway2
reimbursement4
RELYVIRO1
Roche2
RWE1
scenario planning1
SMC1
sotorasib1
SPRITAM1
supply chain1
Synovial Sarcoma1
T Cell Therapy1
tariffs3
TECELRA1
Triastek1
US1

Show more Show less